Reduced dependence on blood collection tube preparation equipment through the expansion of specimen testing equipment
First written in FY2016. 21 of 41 entries say "Worsened", first in FY2017. Latest entry: 2026-08-05.
No other company in this theme has enough history to compare yet.
- 2026-08-05WorsenedEarnings
「Net sales of specimen testing equipment for the cumulative first-quarter period amounted to ¥103,494 thousand, down 14.7% year on year. Competition remains intense and the market environment difficult both domestically and overseas,」
Sales of specimen testing equipment, which is intended to reduce dependence on blood collection tube preparation systems, declined, and the difficult market environment with numerous domestic and overseas competitors continues. - FY2026WorsenedAnnual report
「Revenue from specimen testing equipment for the fiscal year was ¥527.891 million, down 15.1% from the previous fiscal year. In Japan, revenue was ¥295.627 million, down 24.7%, as competition among blood gas analyzer suppliers intensified.」
Full-year revenue from specimen testing equipment, which supports reduced dependence on blood collection tube preparation equipment, fell 15.1%, while domestic revenue fell 24.7%. Overseas revenue increased 1.4%, but overall performance toward reducing dependence deteriorated. - FY2026-H1WorsenedAnnual report
「Revenue from specimen testing equipment for the six months ended ¥290.610 million, down 2.0% year on year. In Japan, sales of blood gas analyzers and electrolyte analyzers recovered slightly, resulting in revenue of ¥162.669 million, up 9.3%. Overseas revenue was ¥127.941 million, down 13.3%, as sales in Asia, particularly the Middle East, fell below the prior-year level.」
Revenue from specimen testing equipment, a means of reducing dependence on blood collection tube preparation equipment, fell 2.0% year on year. Although domestic revenue increased 9.3%, overseas revenue fell 13.3%, bringing overall progress to a halt. - FY2025AdvancedAnnual report
「Revenue from specimen testing equipment for the fiscal year was ¥621.770 million, up 3.8% from the previous fiscal year. In Japan, amid intensifying competition, sales of analyzers other than desktop blood gas analyzers fell below the prior fiscal year, resulting in revenue of ¥392.644 million, down 2.9%. Overseas revenue was ¥229.125 million, up 17.7%, as sales of desktop blood gas analyzers grew in Latin America and Asia.」
Full-year revenue from specimen testing equipment increased 3.8%, while overseas revenue increased 17.7% on growth in sales to Latin America and Asia. Overall performance toward reducing dependence on blood collection tube preparation equipment improved. - FY2025-H1AdvancedAnnual report
「Revenue from specimen testing equipment for the six months ended ¥296.441 million, up 8.6% year on year. In Japan, revenue was ¥148.868 million, down 15.3%, as sales of both desktop and handheld blood gas analyzers, mainly, fell below the prior-year level. Overseas revenue was ¥147.572 million, up 51.8%, mainly because sales of blood gas analyzers to the Middle East and Asia increased.」
First-half revenue from specimen testing equipment increased 8.6% year on year, while overseas revenue increased 51.8% on growth in sales of blood gas analyzers to the Middle East and Asia. Although domestic revenue declined, overall performance toward reducing dependence improved. - FY2024AdvancedAnnual report
「Revenue from specimen testing equipment for the fiscal year was ¥598.996 million, up 1.4% from the previous fiscal year. In Japan, revenue was ¥404.333 million, up 16.6%, as sales of both desktop and handheld models of the core blood gas analyzers increased.」
Full-year revenue from specimen testing equipment increased 1.4% from the previous fiscal year, while domestic sales of desktop and handheld blood gas analyzers increased 16.6%. - FY2024-Q3AdvancedAnnual report
「Revenue from specimen testing equipment for the first nine months ended ¥457.410 million, up 16.7% year on year. In Japan, revenue was ¥290.399 million, up 28.3%, as sales of both desktop and new handheld blood gas analyzers increased. Overseas revenue also edged up 0.8% year on year to ¥167.011 million.」
Revenue from specimen testing equipment increased 16.7% year on year, while revenue in Japan increased 28.3% on growth in sales of desktop and new handheld blood gas analyzers. Overseas revenue also increased 0.8%, improving sales performance toward reducing dependence. - FY2024-Q2AdvancedAnnual report
「Revenue from specimen testing equipment for the first six months ended ¥272.883 million, up 12.9% year on year. Revenue in Japan increased 23.0% to ¥175.674 million, mainly because the new handheld blood gas analyzer increased sales. Overseas revenue was ¥97.209 million, down 1.7%, as sales of desktop blood gas analyzers fell below the prior-year level.」
Revenue from specimen testing equipment increased 12.9% year on year, while sales of new handheld blood gas analyzers in Japan increased 23.0%. Of the means of reducing dependence on blood collection tube preparation equipment, domestic sales showed concrete progress. - FY2024-Q1AdvancedAnnual report
「Revenue from specimen testing equipment for the first quarter ended ¥125.301 million, up 15.0% year on year. Revenue in Japan was ¥82.289 million, up 19.8%, and overseas revenue was ¥43.012 million, up 6.8%, mainly because sales of new handheld blood gas analyzers increased in both Japan and overseas.」
Revenue from specimen testing equipment, a means of reducing dependence, increased 15.0% year on year, as sales of new handheld blood gas analyzers grew in both Japan and overseas. - FY2023AdvancedAnnual report
「Revenue from specimen testing equipment for the fiscal year was ¥591.011 million, up 5.3% from the previous fiscal year. Revenue in Japan was ¥346.781 million, down 1.3%, following the model change for handheld blood gas analyzers and unstable procurement of electrolyte analyzers due to material shortages. Overseas revenue was ¥244.229 million, up 16.1%, mainly because sales of handheld blood gas analyzers increased in response to COVID-19.」
Full-year revenue from specimen testing equipment increased 5.3% from the previous fiscal year, while overseas revenue increased 16.1%. In Japan, procurement instability caused by model changes and material shortages remains, but full-year performance toward reducing dependence on blood collection tube preparation equipment improved from the previous fiscal year. - FY2023-Q3WorsenedAnnual report
「Revenue from specimen testing equipment for the first nine months ended ¥391.924 million, down 6.7% year on year. Revenue in Japan was ¥226.261 million, down 10.8%, due mainly to lower sales while handheld blood gas analyzers were between model changes and to sales declines resulting from unstable procurement of electrolyte analyzers. Overseas revenue was ¥165.662 million, down 0.4%, following promotional campaigns for desktop blood gas analyzers and other initiatives.」
Revenue from specimen testing equipment fell 6.7% year on year, while revenue in Japan fell 10.8%. The factors cited were the period between model changes for blood gas analyzers and unstable procurement of electrolyte analyzers. - FY2023-Q2WorsenedAnnual report
「Revenue from specimen testing equipment for the first six months ended ¥241.794 million, down 6.0% year on year. Revenue in Japan was ¥142.859 million, down 12.1%, due mainly to handheld blood gas analyzers being between model changes and sluggish sales of electrolyte analyzers. Overseas revenue was ¥98.935 million, up 4.4%, as sales of desktop blood gas analyzers recovered.」
Revenue from specimen testing equipment fell 6.0% year on year, and performance toward reducing dependence on blood collection tube preparation equipment deteriorated. In Japan, the factors cited were the period between model changes and sluggish sales of electrolyte analyzers. - FY2023-Q1AdvancedAnnual report
「Revenue from specimen testing equipment for the first quarter ended ¥108.952 million, up 2.2% year on year. In Japan, revenue was ¥68.674 million, up 9.8%, mainly because sales of desktop blood gas analyzers increased.」
Revenue from specimen testing equipment, a means of reducing dependence, increased 2.2% year on year. Sales of desktop blood gas analyzers in Japan increased 9.8%, representing a modest recovery from the decline in revenue in the previous fiscal year. - FY2022WorsenedAnnual report
「Revenue from specimen testing equipment for the fiscal year was ¥561.456 million, down 24.1% from the previous fiscal year.」
Revenue from specimen testing equipment, a means of reducing dependence on blood collection tube preparation equipment, fell 24.1% from the previous fiscal year. The normalization of demand for blood gas analyzers used for emergency testing was identified as a factor. - FY2022-Q3WorsenedAnnual report
「Revenue from specimen testing equipment for the first nine months ended ¥419.973 million, down 22.8% year on year. In both Japan and overseas, demand for blood gas analyzers used for emergency testing, including COVID-19 response, had increased sharply in the prior-year period. Reflecting this reversal, revenue in Japan was ¥253.634 million, down 25.9%, and overseas revenue was ¥166.338 million, down 17.7%.」
Revenue from specimen testing equipment fell 22.8% year on year, resulting in lower revenue in both Japan and overseas. The reversal of demand for emergency testing, including COVID-19 response, in the prior-year period was identified as a factor, and performance toward reducing dependence on blood collection tube preparation equipment has deteriorated. - FY2022-Q2WorsenedAnnual report
「Revenue from specimen testing equipment for the first six months ended ¥257.271 million, down 34.5% year on year. As demand for blood gas analyzers used in emergency testing, including COVID-19 response, normalized, revenue in Japan was ¥162.505 million, down 29.7%. Overseas revenue was ¥94.766 million, down 41.3%, reflecting the reversal of the sharp increase in sales of handheld blood gas analyzers in the prior-year period amid the impact of COVID-19.」
Revenue from specimen testing equipment fell 34.5% year on year, resulting in lower revenue in both Japan and overseas. The factors cited were the normalization of demand for blood gas analyzers used for emergency testing and the reversal of the prior-year increase in sales. - FY2022-Q1WorsenedAnnual report
「Revenue from specimen testing equipment for the first quarter ended ¥106.620 million, down 43.6% year on year. As demand for blood gas analyzers used in emergency testing, including COVID-19 response, normalized, revenue in Japan was ¥62.537 million, down 31.6%, and overseas revenue was ¥44.082 million, down 54.9%.」
Revenue from specimen testing equipment fell 43.6% year on year, resulting in lower revenue in both Japan and overseas. The normalization of demand for blood gas analyzers used for emergency testing, including COVID-19 response, was identified as a factor. - FY2021AdvancedAnnual report
「Revenue from specimen testing equipment for the fiscal year was ¥740.217 million, up 29.7% from the previous fiscal year.」
Revenue from specimen testing equipment, a means of reducing dependence on blood collection tube preparation equipment, increased 29.7% from the previous fiscal year. Overseas, expanded distribution channels for blood gas analyzers and increased demand for emergency testing contributed to growth. - FY2021-Q3AdvancedAnnual report
「Revenue from specimen testing equipment for the first nine months ended ¥544.338 million, up 45.7% year on year. In Japan, revenue was ¥342.279 million, up 15.3%, mainly because sales of desktop blood gas analyzers and electrolyte analyzers exceeded the prior-year level. Overseas revenue was ¥202.058 million, up 163.5%, mainly because sales of handheld blood gas analyzers used for emergency testing and other applications increased, particularly in emerging markets, amid the impact of COVID-19.」
Revenue from specimen testing equipment increased 45.7% year on year, with desktop blood gas analyzers in Japan and handheld blood gas analyzers overseas showing growth. Concrete progress toward reducing dependence on blood collection tube preparation equipment has continued. - FY2021-Q2AdvancedAnnual report
「Revenue from specimen testing equipment for the first six months ended ¥392.693 million, up 48.0% year on year. In Japan, revenue was ¥231.242 million, up 12.2%, mainly as sales of desktop blood gas analyzers and electrolyte analyzers increased year on year. Overseas revenue was ¥161.451 million, up 172.5%, mainly because sales of handheld blood gas analyzers used for emergency testing and other applications increased amid the impact of COVID-19.」
Revenue from specimen testing equipment increased 48.0% year on year, with desktop blood gas analyzers in Japan and handheld blood gas analyzers overseas showing growth. The company has shown concrete progress toward reducing its dependence on blood collection tube preparation equipment. - FY2021-Q1AdvancedAnnual report
「Revenue from specimen testing equipment for the first quarter ended ¥189.101 million, up 64.7% year on year. In Japan, revenue was ¥91.421 million, up 12.5%, reflecting increased sales of desktop blood gas analyzers. Overseas revenue was ¥97.680 million, up 191.0%, mainly because sales of handheld blood gas analyzers used for emergency testing and other applications increased amid the impact of COVID-19.」
Revenue from specimen testing equipment increased 64.7% year on year, driven by desktop blood gas analyzers in Japan and handheld blood gas analyzers overseas. The company has shown concrete progress toward reducing its dependence on blood collection tube preparation equipment. - FY2020WorsenedAnnual report
「Revenue from specimen testing equipment for the fiscal year was ¥570.813 million, down 8.0% year on year. The Company plans to reduce its dependence on the blood collection tube preparation systems business by expanding new products in the specimen testing equipment business. However, it is unclear whether research and development, commercialization and sales plans for the new products will expand as anticipated, and the Company may continue to be heavily dependent on the blood collection tube preparation systems business for its revenue in the future.」
Full-year revenue from specimen testing equipment, a means of reducing dependence, fell 8.0% from the previous fiscal year, and the outlook for growth in new products remains uncertain. - FY2020-Q3WorsenedAnnual report
「Revenue from specimen testing equipment for the cumulative third quarter was ¥373.512 million, down 16.5% year on year. Domestic revenue was ¥296.822 million, down 12.8%, due partly to sluggish sales of higher-end models of the core blood gas analyzers. Overseas revenue was ¥76.690 million, down 28.5%, as sales of both desktop and handheld blood gas analyzers fell below the same period of the previous year.」
Revenue from specimen testing equipment fell 16.5% year on year, with sales of blood gas analyzers declining in both Japan and overseas. Performance toward reducing dependence on blood collection tube preparation systems deteriorated for the cumulative third quarter. - FY2020-Q2WorsenedAnnual report
「Revenue from specimen testing equipment for the cumulative second quarter was ¥265.376 million, down 17.6% year on year. Domestic revenue was ¥206.137 million, down 15.1%, as sales of blood gas analyzers, which had been strong in the same period of the previous year, showed some stagnation. Overseas revenue was ¥59.238 million, down 25.4%, due partly to delays in sales projects for handheld blood gas analyzers.」
Revenue from specimen testing equipment, the means of reducing dependence on blood collection tube preparation systems, fell 17.6% year on year. Sales of blood gas analyzers declined in both Japan and overseas, and performance toward reducing dependence deteriorated. - FY2020-Q1WorsenedAnnual report
「Revenue from specimen testing equipment for the cumulative first quarter was ¥114.837 million, down 22.8% year on year. Domestic revenue was ¥81.271 million, down 32.2%, as sales of blood gas analyzers, which had been strong in the same period of the previous year, showed some stagnation. Overseas revenue was ¥33.566 million, up 16.3%, as strong sales in the Asian market continued.」
Revenue from specimen testing equipment, the means of reducing dependence on blood collection tube preparation systems, fell 22.8% year on year, while domestic revenue fell 32.2%. Overseas revenue increased 16.3% in the Asian market, but overall performance toward reducing dependence deteriorated. - FY2019AdvancedAnnual report
「Revenue from specimen testing equipment for the fiscal year was ¥620.565 million, up 19.9% year on year. Sales of desktop blood gas analyzers remained firm mainly in both the domestic and overseas markets. Domestic revenue was ¥486.977 million, up 19.7%, and overseas revenue was ¥133.588 million, up 20.6%.」
Revenue from specimen testing equipment increased 19.9% year on year, with sales of blood gas analyzers growing in Japan and overseas. Concrete progress toward reducing dependence on blood collection tube preparation systems was shown for the full year. - FY2019-Q3AdvancedAnnual report
「Revenue from specimen testing equipment for the cumulative third quarter was ¥447.502 million, up 33.6% year on year. Sales of blood gas analyzers remained firm for both desktop and handheld models. Domestic revenue was ¥340.284 million, up 25.4%, and overseas revenue was ¥107.217 million, up 68.8%.」
Revenue from specimen testing equipment, the means of reducing dependence on blood collection tube preparation systems, increased 33.6% year on year, with sales of blood gas analyzers growing in Japan and overseas. - FY2019-Q2AdvancedAnnual report
「Revenue from specimen testing equipment for the cumulative second quarter was ¥322.188 million, up 43.5% year on year. Sales of blood gas analyzers, the core products in the specimen testing equipment field, increased for both desktop and handheld models. Domestic revenue was ¥242.773 million, up 33.2%, while overseas revenue was ¥79.414 million, up 88.1%, as sales of the products increased in emerging markets including Asia and Central and South America.」
Revenue from specimen testing equipment increased 43.5% year on year, with sales of blood gas analyzers growing in Japan and overseas. A clear recovery from the previous period's decline was shown toward reducing dependence on blood collection tube preparation systems. - FY2019-Q1AdvancedAnnual report
「Revenue from specimen testing equipment for the cumulative first quarter was ¥148.660 million, up 40.3% year on year. Sales of blood gas analyzers, the core products in the specimen testing equipment field, increased for both desktop and handheld models. Domestic revenue was ¥119.809 million, up 32.0%, and overseas revenue was ¥28.850 million, up 89.8%.」
Revenue from specimen testing equipment, the means of reducing dependence on blood collection tube preparation systems, increased 40.3% year on year, with sales of blood gas analyzers growing in both Japan and overseas. - FY2018WorsenedAnnual report
「The Company plans to reduce its dependence on the blood collection tube preparation systems business by expanding new products in the specimen testing equipment business. However, it is unclear whether research and development, commercialization and sales plans for the new products will expand as anticipated, and the Company may continue to be heavily dependent on the blood collection tube preparation systems business for its revenue in the future. Revenue from specimen testing equipment for the fiscal year was ¥517.704 million, down 3.2% year on year.」
Revenue from specimen testing equipment, the means of reducing dependence, fell 3.2% year on year, and the Company continues to recognize that expansion of new products remains uncertain. - FY2018-Q3WorsenedAnnual report
「Revenue from specimen testing equipment for the cumulative third quarter was ¥334.954 million, down 8.2% year on year.」
Revenue from specimen testing equipment, the means of reducing dependence on blood collection tube preparation systems, fell 8.2% year on year, and performance toward reducing dependence deteriorated. - FY2018-Q2WorsenedAnnual report
「Revenue from specimen testing equipment for the cumulative second quarter was ¥224.451 million, down 7.6% year on year.」
Revenue from specimen testing equipment, the means of reducing dependence on blood collection tube preparation systems, fell 7.6% year on year. Overseas revenue increased 63.2%, but domestic revenue fell 16.0%, resulting in an overall deterioration. - FY2018-Q1WorsenedAnnual report
「Revenue from specimen testing equipment for the cumulative first quarter was ¥105.937 million, down 6.8% year on year. Domestic revenue was ¥90.736 million, up 3.4%, as sales, led by blood gas analyzers, grew. Overseas revenue was ¥15.201 million, down 41.2%, as sales to the Asian market, which had been strong in the same period of the previous year, showed signs of stagnation.」
Revenue from specimen testing equipment, the means of reducing dependence on blood collection tube preparation systems, fell 6.8% year on year, while overseas revenue fell 41.2%. Although domestic sales of blood gas analyzers increased, overall progress toward reducing dependence deteriorated. - FY2017WorsenedAnnual report
「Going forward, the Company plans to reduce its dependence on the blood collection tube preparation systems business by expanding new products in the specimen testing equipment business. However, it is unclear whether research and development, commercialization and sales plans for the new products will expand as anticipated, and the Company may continue to be heavily dependent on the blood collection tube preparation systems business for its revenue in the future.」
While the Company has stated its policy of reducing dependence, the outlook for research and development, commercialization and sales expansion of new products remains uncertain, and it explicitly indicates that dependence may remain substantial. Revenue from specimen testing equipment also fell 1.7% year on year. - FY2017-Q3AdvancedAnnual report
「Revenue from specimen testing equipment for the cumulative third quarter was ¥364.988 million, up 16.1% year on year. As the Company actively promoted sales of blood gas and electrolyte analyzers in Japan and overseas, domestic revenue was ¥272.699 million, up 3.2%, and overseas revenue was ¥92.289 million, up 84.2%.」
Revenue from specimen testing equipment increased 16.1% year on year, while overseas revenue increased 84.2% on sales of blood gas and electrolyte analyzers. This was described as concrete progress toward reducing dependence on blood collection tube preparation systems. - FY2017-Q2RestatedAnnual report
「The Company will focus on stimulating replacement demand in the domestic market and developing overseas markets, centered on new blood collection tube preparation systems and specimen testing equipment. It aims to increase cumulative unit sales while steadily expanding related sales of consumables and other products.」
The Company continues to pursue a policy centered on new specimen testing equipment. First-half revenue from specimen testing equipment increased 0.6% year on year, and no clear additional milestone toward reducing dependence was indicated. - FY2017-Q1AdvancedAnnual report
「Revenue from specimen testing equipment for the cumulative first quarter was ¥113.620 million, up 38.3% year on year. Sales of analytical equipment, including blood gas analyzers, remained firm in both the domestic and overseas markets」
Revenue from specimen testing equipment, which is intended to reduce dependence on the blood collection tube preparation systems business, increased 38.3% year on year, with sales of blood gas analyzers and other products remaining firm in Japan and overseas. - FY2016First statedAnnual report
「Going forward, the Company plans to reduce its dependence on the blood collection tube preparation systems business by expanding new products in the specimen testing equipment business.」
The Company plans to expand new specimen testing equipment products to reduce its dependence on its core business.